China Isotope & Radiation Corp. (HK:1763)
:1763
Want to see HK:1763 full AI Analyst Report?
Top Page
China Isotope & Radiation Corp.
(1763)
Select Model
Select Model
Rating:56Neutral
Price Target:
HK$19.50
▼(-17.09% Downside)
Action:DowngradedDate:04/26/26
The score is held back primarily by mixed financial performance—2025 revenue contraction, thin net margins, and especially volatile free cash flow—alongside bearish technical trends (price below key moving averages and negative MACD). These are partly offset by a supportive valuation (low P/E and ~3% dividend yield).
Positive Factors
High operating profitability
Sustained mid-teens EBITDA and double-digit EBIT margins indicate a structurally profitable core business in isotope and irradiation services. Durable operating margins provide a buffer against demand swings, support reinvestment in specialty technology, and underpin long-term cash generation even if top-line growth slows.
Negative Factors
Revenue contraction in 2025
A material revenue decline after prior growth suggests demand weakness or competitive/market pressures that could persist. Lower top-line reduces operating leverage benefits, limits ability to scale fixed-cost recovery, and constrains future reinvestment and margin stability if not reversed.
Read all positive and negative factors
Positive Factors
Negative Factors
High operating profitability
Sustained mid-teens EBITDA and double-digit EBIT margins indicate a structurally profitable core business in isotope and irradiation services. Durable operating margins provide a buffer against demand swings, support reinvestment in specialty technology, and underpin long-term cash generation even if top-line growth slows.
Read all positive factors
China Isotope & Radiation Corp. (1763) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.02B
Dividend Yield2.76%
Average Volume (3M)508.32K
Price to Earnings (P/E)18.2
Beta (1Y)0.82
Revenue Growth-4.92%
EPS Growth-19.51%
CountryHK
Employees3,367
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.53
Shares Outstanding79,968,800
10 Day Avg. Volume533,840
30 Day Avg. Volume508,324
Financial Highlights & Ratios
PEG Ratio-0.86
Price to Book (P/B)1.11
Price to Sales (P/S)0.83
P/FCF Ratio10.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Isotope & Radiation Corp. Business Overview & Revenue Model
Company Description
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates t...
How the Company Makes Money
null...
China Isotope & Radiation Corp. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
70
Positive
Cash Flow
45
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.00B | 7.57B | 6.63B | 6.15B | 5.14B |
| Gross Profit | 3.52B | 3.68B | 3.48B | 3.51B | 3.24B |
| EBITDA | 1.17B | 1.28B | 1.22B | 1.05B | 901.43M |
| Net Income | 318.95M | 406.64M | 370.97M | 392.27M | 335.75M |
Balance Sheet | |||||
| Total Assets | 15.72B | 14.77B | 13.19B | 11.69B | 10.47B |
| Cash, Cash Equivalents and Short-Term Investments | 2.59B | 2.63B | 2.94B | 2.93B | 2.79B |
| Total Debt | 2.73B | 2.57B | 1.70B | 903.86M | 856.63M |
| Total Liabilities | 7.59B | 7.02B | 6.05B | 5.13B | 4.44B |
| Stockholders Equity | 5.23B | 5.01B | 4.69B | 4.47B | 4.18B |
Cash Flow | |||||
| Free Cash Flow | 538.34M | 142.48M | -812.66M | 328.66M | 366.59M |
| Operating Cash Flow | 538.34M | 142.48M | 84.96M | 862.66M | 794.31M |
| Investing Cash Flow | -348.92M | -564.81M | -429.88M | -506.62M | -907.36M |
| Financing Cash Flow | -168.80M | 499.70M | 484.37M | -291.50M | -97.44M |
China Isotope & Radiation Corp. Technical Analysis
Negative
23.52
Price Trends
20.63
Negative
21.13
Negative
19.06
Negative
Market Momentum
-0.59
Positive
29.56
Positive
13.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1763, the sentiment is Negative. The current price of 23.52 is above the 20-day moving average (MA) of 20.05, above the 50-day MA of 20.63, and above the 200-day MA of 19.06, indicating a bearish trend. The MACD of -0.59 indicates Positive momentum. The RSI at 29.56 is Positive, neither overbought nor oversold. The STOCH value of 13.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1763.
China Isotope & Radiation Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$7.67B | 17.31 | 11.91% | 1.26% | 10.19% | 23.37% | |
72 Outperform | HK$7.89B | 27.86 | 4.88% | 0.48% | 35.28% | 146.71% | |
71 Outperform | HK$7.73B | 16.13 | 9.39% | 1.88% | 29.94% | 119.16% | |
56 Neutral | HK$6.02B | 18.20 | 6.19% | 2.76% | -4.92% | -19.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$3.32B | -4.06 | -6.63% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:1763
China Isotope & Radiation Corp.
18.90
7.82
70.58%
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
23.14
4.75
25.80%
HK:1789
AK Medical Holdings Ltd.
6.84
1.14
20.00%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
12.50
3.86
44.68%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.58
-1.92
-42.67%
China Isotope & Radiation Corp. Corporate Events
China Isotope & Radiation Corp Declares 2025 Final Dividend and Sets Tax Terms for H Shareholders
Mar 27, 2026
China Isotope Radiation Corporation has declared a final ordinary cash dividend of RMB 0.2264 per share for the financial year ended 31 December 2025, subject to shareholder approval at a meeting scheduled for 18 June 2026. The dividend for H sha...
China Isotope & Radiation’s 2025 Profit Drops on Equipment Procurement Delays, Underlying Earnings Improve
Mar 27, 2026
China Isotope Radiation Corporation reported 2025 revenue of RMB7.19 billion, down 5.1% year on year, mainly due to delayed centralized procurement of Class A large-scale nuclear medicine equipment. Net profit fell 24.4% to RMB664.5 million, with...
China Isotope & Radiation Expands NDT Footprint With Majority Stake in Huifeng Detection
Mar 19, 2026
China Isotope Radiation Corporation said its subsidiary Chengdu Gaotong Isotope has agreed to acquire a 51% stake in Hunan Huifeng Engineering Detection, a specialist in non-destructive testing and special equipment inspection. Huifeng Detection ...
China Isotope & Radiation Sets March 2026 Board Meeting for 2025 Results, Dividend Plan
Mar 17, 2026
China Isotope Radiation Corporation has scheduled a board meeting on 27 March 2026 to review and approve its annual results for the financial year ended 31 December 2025. The board will also consider recommending a final dividend, signaling the c...
CIRC Strikes Strategic Nuclear Technology Pact With Maoming City Government
Mar 13, 2026
China Isotope Radiation Corporation and its subsidiary Zhonghe Headway have signed a strategic cooperation agreement with the People’s Government of Maoming Municipality in Guangdong Province. The partnership aims to pool resources and poli...
China Isotope & Radiation Expands Breath Diagnostics With New Hematology Device Approval
Mar 2, 2026
China Isotope Radiation Corporation announced that its subsidiary Anhui Young-Hearty Medical Appliance Equipment has secured a Class II Medical Device Registration Certificate in China for a self-developed Red Blood Cell Lifespan Measurement Bre...
China Isotope & Radiation issues profit warning on 2025 results
Feb 12, 2026
China Isotope Radiation Corporation has warned investors that its 2025 revenue is expected to fall to about RMB6.98 billion–RMB7.21 billion, a year-on-year decline of roughly 5%–8%. Net profit is projected at RMB611 million–RMB6...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.